Empowered Patient Podcast Next-Generation Antibody-Drug Conjugate for Treating Lung Cancer with George Eliades Mythic Therapeutics
George Eliades, the CEO of Mythic Therapeutics a company focused on the next generation of antibody-drug conjugates, ADCs, to treat cancer. Their approach aims to expand the population of patients who can benefit from ADCs by targeting proteins expressed at low levels on cancer cells. The company's lead candidate targets the MET protein in non-small cell lung cancer cells and is designed to deliver chemotherapy more selectively and effectively to cancer cells using the FateControl ™ technology.
George explains, "We try to be different in two important ways for patients. If you think about ADCs, they've been around for a long time with the promise of bringing chemotherapy-like efficacy, but the safety of a targeted therapy because so much less chemo is being administered to the patient and that chemo is going directly, at least in theory, to the cancer cell. That was sort of the first promise. The second thing that's happened over the years is that the patients who benefit from ADCs tend to be a very small subset of patients, and those are the patients who express a very high level of the target. Generally, it's a protein on the cancer cell that the ADC binds to. And if you don't have a high level of that target expression in general, you don't benefit as much from the ADC."
"What we're trying to do is two things. Number one, we're trying to make it so more patients can benefit from ADCs and bring it to the patients who have low expressions of those proteins we're trying to target. And the second thing that we're trying to do is deliver on the initial promise. When I say that, I mean to have a drug that is very tolerable for patients but gives them the tumor shrinkage that the patient wants. Also it lets them stay on the drug without feeling terrible so they can get on with their day."
#MythicTherapeutics #ADCs #AntibodyDrugConjugate #FateControl #NSCLC #LungCancer #Oncology